$2.23
-0.09 (-3.88%)
Open$2.28
Previous Close$2.32
Day High$2.29
Day Low$2.17
52W High$4.54
52W Low$0.91
Volume—
Avg Volume1.26M
Market Cap227.06M
P/E Ratio—
EPS$-1.88
SectorBiotechnology
Analyst Ratings
Buy
20 analysts
Price Target
+474.4% upside
Current
$2.23
$2.23
Target
$12.81
$12.81
$8.62
$12.81 avg
$14.59
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 44.69M | 35.15M | 30.54M |
| Net Income | -176,521,931 | -124,946,706 | 4.38M |
| Profit Margin | -395.0% | -375.3% | 14.4% |
| EBITDA | -173,057,262 | -129,299,566 | 9.59M |
| Free Cash Flow | — | — | 5.15M |
| Rev Growth | +27.2% | +27.2% | +16.6% |
| Debt/Equity | 2.15 | 2.15 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |